Biotech · Public company · Newport Beach, CA, US
Evolus, Inc.
Ticker EOLS · SEC CIK 0001570562
Track this companyFree. Adds Evolus, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials91 recruiting or active
Pipeline programs5From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline5
- Botulinum toxin, Type APhase 3 · Glabellar Frown LinesClinicalTrials.gov · fetched Nov 12, 2026
- Botulinum purified neurotoxin, Type APhase 2 · Glabellar Frown LinesClinicalTrials.gov · fetched Nov 12, 2026
- DWP-450 (Botulinum purified neurotoxin, Type A)Phase 2 · Glabellar Frown LinesClinicalTrials.gov · fetched Nov 12, 2026
- OnabotulinumtoxinAPhase 2 · Glabellar Frown LinesClinicalTrials.gov · fetched Nov 12, 2026
- PrabotulinumtoxinA-XvfsPhase 2 · Glabellar Frown LinesClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials9
- BoTox Into the Sternocleidomastoid Muscles (SCM)PHASE4 · RECRUITING · started May 14, 2025ClinicalTrials.gov NCT06903975 · fetched Nov 12, 2026
- Effects of Microtox on Facial Skin Quality, Fine Wrinkles, and TexturePHASE1 · COMPLETED · started Sep 3, 2024ClinicalTrials.gov NCT06604832 · fetched Nov 12, 2026
- Spread of PrabotulinumtoxinA-xvfs Versus OnabotulinumtoxinA in the Treatment of Forehead RhytidesEARLY_PHASE1 · COMPLETED · started May 1, 2023ClinicalTrials.gov NCT05807412 · fetched Nov 12, 2026
- Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar LinesPHASE2 · COMPLETED · started Mar 30, 2022ClinicalTrials.gov NCT05320393 · fetched Nov 12, 2026
- Jeuveau Treatment of Glabellar Lines Using OLD Versus COLDEARLY_PHASE1 · COMPLETED · started Dec 16, 2021ClinicalTrials.gov NCT05129319 · fetched Nov 12, 2026
- Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006PHASE2 · COMPLETED · started May 1, 2015ClinicalTrials.gov NCT02428608 · fetched Nov 12, 2026
- A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV001PHASE3 · COMPLETED · started Jan 1, 2015ClinicalTrials.gov NCT02334423 · fetched Nov 12, 2026
- A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002PHASE3 · COMPLETED · started Jan 1, 2015ClinicalTrials.gov NCT02334436 · fetched Nov 12, 2026
- Safety Study of DWP-450 (Botulinum Purified Neurotoxin, Type A) Injection to Treat Glabellar LinesPHASE2 · COMPLETED · started Aug 1, 2014ClinicalTrials.gov NCT02184988 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 4, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 8, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 12, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 13, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Mar 3, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 3, 2026 · fetched Nov 12, 2026